Selexis’ innovative technologies and world-class expert services significantly reduce the time, effort, and costs that are associated with developing high-performance mammalian cell lines for therapeutic protein production (e.g., MAbs, growth factors, enzymes).
The Selexis SUREtechnology Platform™ provides our partners with a single program that can be used for a wide range of applications, from drug discovery to biologics manufacturing. Selexis is proud of its work with global partners that span the full spectrum of life sciences, from academic research to biotechnology development and big pharma manufacturing. SUREtechnology has generated more than 100 drug candidates in clinical development and four commercial products, representing one of the industry’s largest portfolios.
Our SUREtechnology has made it possible to generate stable and high-performing manufacturing cell lines in approximately three months from the time of transfection, with productivity levels reaching 1-7 g/L for monoclonal antibodies (fed-batch culture in shake flask), reducing the need for larger bioreactor capacity.
We have also developed well-defined cell culture conditions, media, and seeding and feeding parameters (SUREfeed Strategy™) for our proprietary SURE CHO-M Cell Line™ and can carry out initial scale-up optimization into 1–2-L bioreactors. As a result, the Selexis SUREdevelopment Process™ improves productivity and jump starts the scale-up process for CMOs, resulting in faster biomanufacturing timelines and reduced development costs.